Vertex Pharmaceuticals Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-10-16
Other years: 2026 vs 2025
⚠ AI Risk Brief Interpretation layer — deterministic data below

Third-party dependency and supply chain risks intensified significantly; manufacturing, reimbursement, and foreign operations remain elevated threats.

Direction ↑ More concerning
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
16
Modified
42
Unchanged
🟢 New in Current Filing Disclosure change7/10

We rely on third parties to carry out our operations. Failure to maintain our third-party relationships or challenges at or with these third parties could materially harm our business.

🟡 Modified If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions, and fines that could have a material adverse effect on our business, financial condition, results of operations and growth prospects. 🔒
🟡 Modified We may face manufacturing, supply, and distribution difficulties, among other challenges, delays, or interruptions, including at our third-party providers. 🔒
🟡 Modified A variety of risks associated with operating in foreign countries could materially adversely affect our business. 🔒

And 13 more changes in the full comparison.

16 changes in this historical filing

The complete historical comparison (2025 vs 2024) is available on the Pro plan.

Get Pro access Already a Pro subscriber? View full diff →